Vanguard Health Care ETF

Most Recent

  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 3Q17 Revenue Estimates Could Reveal Growth

    Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.

    By Mike Benson
  • uploads///Chart  Product
    Earnings Report

    Pfizer’s Key Product Developments in 1Q17

    To strengthen the innovative health business, the company is focusing on the development of new drugs as well as expanding the market reach of existing products.

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    A Look Back at Eli Lilly’s 2016 Revenue Trends

    Eli Lilly (LLY) reported a ~6% rise in its revenue to $21.2 billion in 2016, compared to its revenue of $20.0 billion in 2015.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Emerging Markets Drive Abbott’s Nutritional Business Growth

    In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.

    By Margaret Patrick
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Pfizer Expands Its Investment Portfolio through Pfizer Ventures

    On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.

    By Mike Benson
  • uploads///generic drug savings
    Company & Industry Overviews

    Will Generic Drugs Help Curb Healthcare Costs?

    Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Recommendations for Pfizer

    Analysts expect Pfizer (PFE) to see adjusted EPS of $0.74 in Q2 2018.

    By Mike Benson
  • uploads///ELOS
    Fund Managers

    Baupost Group Slightly Reduced Its Stake in Syneron Medical

    The Baupost Group lowered its position in Syneron Medical (ELOS) during 4Q14. The position accounted for a minor 0.4% of the total portfolio in 4Q14.

    By Samantha Nielson
  • uploads///strategic initiatives
    Company & Industry Overviews

    What Analysts Are Recommending Now for Baxter International

    Analysts estimate a potential return of ~12.4% for Baxter’s stock over the next 12 months, with a 12-month target price of $40.44 per share.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Developments for Allergan in June

    Allergan develops various products through internal programs and in collaboration with other companies.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q16 Earnings

    Johnson & Johnson is set to release its 4Q16 earnings on January 24, 2017.

    By Mike Benson
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
  • uploads///II Pipeline
    Company & Industry Overviews

    What’s in Celgene’s Immunology and Inflammation Clinical Pipeline?

    Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Universal Health Services’ Net Profit Margin Expected to Rise

    Wall Street analysts expect that Universal Health Services (UHS) will report higher net profit margins in 3Q15 compared to margins in 3Q14.

    By Margaret Patrick
  • uploads///renal
    Earnings Report

    AMIA APD Momentum Drives Baxter’s Renal Business Growth in 1Q16

    Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$898 million, or ~38%, came from Baxter’s Renal Products business.

    By Sarah Collins
  • uploads/// US Household saving rate
    Real Insights

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index jumped to a 14-year high…

    By VanEck
  • uploads///BaupostF
    Fund Managers

    Analyzing The Baupost Group’s Holdings in 4Q14

    The Baupost Group generated $21.5 billion in returns over its history. The recent 13F filing revealed that its 4Q14 portfolio declined more to $5.09 billion.

    By Samantha Nielson
  • uploads///Chart
    Company & Industry Overviews

    Is Incyte Hurt by Having Only One FDA-Approved Drug?

    Jakafi (ruxolitinib) is Incyte’s only product and the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, rare types of blood cancer.

    By Mike Benson
  • uploads///Uninsured Rate Among Non elderly People On Decline
    Macroeconomic Analysis

    Can Auto-Enrollment in Obamacare Outdo the Individual Mandate?

    Auto-enrollment is now being considered as an alternative to the individual mandate of Obamacare—something that would reduce the current penalty to $0.

    By Mary Sadler
  • uploads///Graph
    Earnings Report

    Customer Growth Drove CI’s Global Supplemental Benefits Business

    In 2015, Cigna’s (CI) global supplemental benefits business earned revenues of about $3.1 billion, year-over-year (or YoY) growth of about 4.8%.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Pharmaceuticals Segment in 2Q17

    Pharmaceuticals segment Johnson & Johnson’s (JNJ) pharmaceutical segment comprises the cardiovascular, metabolics, immunology, infectious disease, neuroscience, oncology, and pulmonary hypertension franchises. Cardiovascular and metabolics franchise The cardiovascular and metabolics franchise reported revenue of $1.6 billion in 2Q17, a decrease of ~6.5% from 2Q16. The decline was driven by lower sales of Invokana due to discounts […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Eli Lilly’s Clinical and Business Developments in 1Q16

    Elanco, the animal healthcare arm of Eli Lilly, received exclusive and global rights to develop and commercialize Aratana’s (PETX) Gallipart, a drug that treats osteoarthritis in dogs.

    By Mike Benson
  • uploads///Sterile Injection revenues
    Company & Industry Overviews

    Understanding Pfizer’s Sterile Injection Pharmaceuticals Position in 2017

    In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Picture
    Miscellaneous

    Could Repeal of Obamacare Boost the Healthcare Sector?

    The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the healthcare sector, showed a weaker performance in March 2017.

    By Sarah Sands
  • uploads///Chart  New
    Company & Industry Overviews

    Quarterly Performance of Eli Lilly’s New Products

    Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16.

    By Mike Benson
  • uploads///calculator _
    Consumer

    How to Invest Like Jeff Bezos: The Top Three Sectors to Watch

    Jeff Bezos’s primary focus remains his role as the CEO of Amazon, but he’s made investments in many other industries and companies.

    By Jitendra Parashar
  • uploads///Sharpe Ratio Example
    Financials

    Sharpe ratio shows healthcare ETFs are a strong relative investment

    Adjusting performance on a risk basis As new insurees flood the insurance market and baby boomers approach retirement, the healthcare space should expect dramatic increases in demand. Alongside an increase in demand, however, has been a tightening of reimbursement policy and a more stringent regulatory environment. These variables present unique risks and opportunities for healthcare […]

    By Amritpal Khalsa
  • uploads///close up _
    Company & Industry Overviews

    What Analysts Recommend for Johnson & Johnson after Q4 Results

    The 12-month consensus analyst recommendation for Johnson & Johnson on January 29 was a “buy.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts Recommending for Mylan in January?

    Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Must-Know Developments for Ionis Pharmaceuticals in 2018

    On February 20, 2018, Ionis announced that the company has licensed the drug IONIS-AZ5-2.5Rx to AstraZeneca (AZN).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Johnson & Johnson’s Profit Margins in 4Q17

    Johnson & Johnson’s gross profit margin decreased to 64.1% in 4Q17, a ~5% decrease compared to 69.1% in 4Q16.

    By Mike Benson
  • uploads///medical device business
    Company & Industry Overviews

    What’s ahead for Abbott Laboratories’ Medical Device Unit?

    Abbott Laboratories’ (ABT) Medical Device segment is its largest business division, contributing ~36% to the company’s total sales in 4Q17.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings

    Eli Lilly (LLY) plans to release its 4Q17 and 2017 earnings on January 31, 2018. For 4Q17, analysts expect LLY to report earnings per share of $1.07 on revenues of ~$5.9 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Are Pfizer’s Positive Growth Contributors?

    Lurica, one of the blockbuster drugs from Pfizer’s portfolio, is expected to report revenue growth during 4Q17—likely driven by increased US sales.

    By Mike Benson
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Chart  CIR
    Company & Industry Overviews

    Merck & Co.’s Cardiovascular and Immunology Products in 3Q17

    In Merck’s cardiovascular product portfolio, Adempas reported revenues of $70 million in 3Q17 compared to $48 million in 3Q16.

    By Mike Benson
  • uploads///Chart  Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates

    For 4Q17, revenues for Johnson & Johnson’s immunology franchise are expected to increase due to the strong performance of Stelara.

    By Mike Benson
  • uploads///Insys priorities
    Company & Industry Overviews

    Insys Has Legal Issues Galore

    In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.

    By Kenneth Smith
  • uploads///How it works
    Company & Industry Overviews

    What’s the Competitive Landscape for Accelerate Diagnostics?

    Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Examining Incyte’s Quarterly Revenue Trend

    Incyte’s revenue sources include revenue from Iclusig sales in European markets, Jakafi sales in US markets, and royalties from Jakavi and Olumiant sales.

    By Mike Benson
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Eli Lilly’s Neuroscience Products Portfolio in 3Q17

    Eli Lilly’s Strattera had revenues of $137 million in 3Q17, a decline of ~31% compared to $199 million in 3Q16.

    By Mike Benson
  • uploads///Zytiga
    Company & Industry Overviews

    How Johnson & Johnson’s Zytiga Performed in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) Zytiga generated revenues of $669 million, which reflected ~15% growth on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Expects Eucrisa to Report Sales of ~$2.0 Billion

    Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]

    By Margaret Patrick
  • uploads///Chart  OP
    Company & Industry Overviews

    Gilead’s Other Products in 3Q17

    Gilead’s other products As discussed earlier, Gilead Sciences’ (GILD) other products include cardiovascular, inflammation, oncology, and respiratory products. The above chart compares Gilead’s revenue from other products over the last few quarters. Between 3Q16 and 3Q17, revenue from other products fell 1% to $559 million from $564 million. Cardiovascular drugs Letairis, Lexiscan, and Ranexa are Gilead’s cardiovascular products. […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Final Data from Keynote-189 Study by February 2019

    In its 3Q17 earnings conference call, Merck & Co. (MRK) announced its plans to capture long-term overall survival data in its pivotal Keynote-189 study.

    By Margaret Patrick
  • uploads///Alimta
    Company & Industry Overviews

    An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

    In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Recent Developments for Merck’s Keytruda

    Merck & Co.’s (MRK) Keytruda (pembrolizumab) sales increased ~194% in 3Q17 to ~$1.1 billion.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17

    Eli Lilly’s cardiovascular franchise includes the drugs Cialis and Effient, but for 3Q17, both drugs reported lower sales.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Gauging Exelixis’s High Hopes for Cotellic

    On November 10, 2015, the FDA approved Exelixis’s (EXEL) Cotellic in combination with Roche Holdings’ (RHHBY) Zelboraf (vemurafenib) as a treatment option.

    By Margaret Patrick
  • uploads///s
    Company & Industry Overviews

    Key Launches Expected to Drive Zimmer Biomet’s Sales

    Zimmer Biomet Holdings’ (ZBH) S.E.T. (Sports, Extremities, and Trauma) segment registered sales of $407 million, contributing 23% to the company’s total revenues.

    By Sarah Collins
  • uploads///Chart  Ratings
    Earnings Report

    Pfizer on the Street: Analyst Ratings and Recommendations

    Wall Street analysts estimate that Pfizer’s top line will rise 1% YoY to ~$13.18 billion in 3Q17. Its EPS (earnings per share) are expected to rise to $0.64.

    By Mike Benson
  • uploads///Chart  ABBV
    Healthcare

    AbbVie Stock: Performance in 3Q17

    AbbVie stock price has risen ~22.5% in 3Q17. It has risen ~54.1% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Taltz
    Company & Industry Overviews

    How Eli Lilly’s Taltz Is Positioned after 1H17

    In 1H17, Eli Lilly’s (LLY) Taltz reported revenues of ~$235.3 million, compared with $19.3 million in 1H16.

    By Daniel Collins
  • uploads///stock price
    Company & Industry Overviews

    Intuitive Surgical’s Recent Stock Split: The Market Reaction

    On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Focused on Efficacy and Safety of LVAD Offerings

    Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

    By Margaret Patrick
  • uploads///Collaboration
    Company & Industry Overviews

    Behind Jazz’s Strategic Collaboration with ImmunoGen

    In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.

    By Daniel Collins
  • uploads///Chart  NewProducts
    Company & Industry Overviews

    Eli Lilly’s New Products in 2Q17

    Trulicity’s sales totaled $480.2 million during 2Q17, representing growth exceeding 100% compared to $201.3 million during 2Q16.

    By Mike Benson
  • uploads///
    Industrials

    What Stocks Should Be on Your Radar amid Geopolitical Tensions

    Renewed tensions arising out of North Korea’s missile launch on Tuesday had a major impact on volatility. Asian markets have declined more than 1% as risk aversion dominated markets.

    By Ricky Cove
  • uploads///RD
    Company & Industry Overviews

    How Innovation Is Driving Becton Dickinson’s Growth in 2017

    Becton Dickinson (BDX) has seen tremendous growth in recent years, driven by some of its major acquisitions and key product launches.

    By Sarah Collins
  • uploads///Chart  Dev
    Company & Industry Overviews

    Key Developments for Allergan in 2Q17

    Allergan (AGN) is a leading pharmaceuticals company involved with pharmaceuticals, over-the-counter products, eye care, and aesthetics products.

    By Mike Benson
  • uploads///Vectibix revenues
    Company & Industry Overviews

    What We May See from Amgen’s Vectibix in 2017

    Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]

    By Daniel Collins
  • uploads///
    Miscellaneous

    Which Stocks Will Benefit the Most from US-Korea Tensions?

    Some companies benefit in times of uncertainty, and some sectors provide cover for investors.

    By Ricky Cove
  • uploads///Upadacitinib
    Company & Industry Overviews

    Upadacitinib: Opportunity for AbbVie’s Long-Term Growth?

    ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz.

    By Daniel Collins
  • uploads///Chart  Animal
    Earnings Report

    Eli Lilly’s Elanco in 2Q17

    Elanco’s revenues fell 9.0% to $784.8 million during 2Q17 compared to $859.8 million during 2Q16.

    By Mike Benson
  • uploads///Praluent revenues
    Company & Industry Overviews

    Praluent Could Witness Steady Growth in 2017

    In 2016, Regeneron Pharmaceuticals’ Praluent reported revenue of ~$116.3 million, compared to $10.5 million in 2015.

    By Daniel Collins
  • uploads///Chart  SWR
    Earnings Report

    A Look at Johnson & Johnson’s Segment-Wise Performance

    Segment-wise performance Johnson & Johnson (JNJ) reported a revenue increase of ~2.9% between 2Q16 and 2Q17. The company’s business is broken down into three business segments: Pharmaceuticals, Consumer Products, and Medical Devices. At constant exchange rates, the company reported growth across all segments. Segment-wise revenue The pharmaceutical segment, which contributes nearly 45.8% of Johnson & Johnson’s […]

    By Mike Benson
  • uploads///Cardiovascular Franchise revenues
    Company & Industry Overviews

    Merck’s Cardiovascular Drugs Franchise Could Witness a Modest Fall in 2017

    Vytorin is a combination drug consisting of ezetimibe and simvastatin. Outside the US, the drug is marketed as Inegy.

    By Daniel Collins
  • uploads/// Bayer
    Real Insights

    How Bayer Is Creating Value through Innovation

    In 2016, Bayer owned ~51,000 valid patent applications and patents relating to ~5,000 protected inventions worldwide.

    By VanEck
  • uploads/// Bristol
    Real Insights

    How Bristol-Meyers Squibb Has Benefited from Intangible Assets

    Bristol-Meyers Squibb considers its people to be its competitive advantage, and it plans to build long-term, sustainable growth through innovation.

    By VanEck
  • uploads///Eliquis Revenues
    Company & Industry Overviews

    Why Bristol-Myers Squibb’s Empliciti Matters in 2017

    In 2016, Bristol-Myers Squibb’s (BMY) Empliciti reported revenues of ~$133 million. The US accounted for ~89% of Empliciti’s total revenues.

    By Daniel Collins
  • uploads///Spinraza revenues
    Company & Industry Overviews

    Spinraza May Significantly Boost Biogen’s Revenue Growth

    Spinraza (nusinersen) is a biologic drug indicated for the treatment of spinal muscular atrophy (or SMA).

    By Daniel Collins
  • uploads///Chart  Checkmate
    Company & Industry Overviews

    Data from the Checkmate-205 Study Evaluating Opdivo

    Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart  Tanezumab
    Company & Industry Overviews

    FDA Grants Fast-Track Designation to Tanezumab

    Tanezumab is an investigational drug co-developed by Eli Lilly (LLY) and Pfizer (PFE).

    By Mike Benson
  • uploads///Duodopa Revenues
    Company & Industry Overviews

    A Look at AbbVie’s Neuroscience Portfolio

    In 2016, AbbVie’s (ABBV) Duodopa, a combination drug for the treatment of advanced Parkinson’s disease, generated revenue of ~$293 million.

    By Daniel Collins
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Performance of Eli Lilly’s Neuroscience Products in 1Q17

    Strattera, a drug for the treatment of ADHD, reported 4% growth in its 1Q17 revenues to $196.2 million, compared to $188.1 million for 1Q16.

    By Mike Benson
  • uploads///MASS SPECTROMETRY
    Company & Industry Overviews

    What Does Thermo Fisher Want in the Clinical Mass Spectrometry Business?

    Thermo Fisher Scientific (TMO) is focused on strengthening its mass spectrometry business, which is part of its Analytical Instruments segment.

    By Sarah Collins
  • uploads///asia pacific
    Company & Industry Overviews

    How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?

    Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.

    By Sarah Collins
  • uploads///Chart  Pharmaceuticals
    Company & Industry Overviews

    How JNJ’s Pharmaceuticals Segment Performed in 1Q17

    Johnson & Johnson’s Ppharmaceuticals segment includes products from various franchises: cardiovascular and metabolics, immunology, infectious disease, neuroscience, and oncology.

    By Mike Benson
  • uploads///Medical Devices Market Share as of
    Macroeconomic Analysis

    Is Medical Technology Driving the US Healthcare Industry?

    The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market.

    By Mary Sadler
  • uploads///Rising Contribution in Private Health Insurance
    Macroeconomic Analysis

    Rising Costs Are a Major Issue in the Healthcare Sector

    The US economy is dealing with rising healthcare costs. The national healthcare expenditure grew 5.8% to $3.2 trillion in 2015 or $9,990 per person.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Keytruda Saw Impressive Growth in 2016

    Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.

    By Mike Benson
  • uploads///Performance of Allergan
    Fund Managers

    David Tepper on Allergan: Does It Look Cheap?

    Allergan stock has had a weaker performance in the last year with a fall of nearly 14.9%.

    By Sarah Sands
  • uploads///Chart
    Company & Industry Overviews

    Who Is Incyte Collaborating With?

    Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Major Product Developments in 4Q16

    To strengthen the Innovative Health business, Pfizer is focused on developing new drugs as well as expanding the market reach of existing products.

    By Mike Benson
  • uploads///Chart  NewProducts
    Company & Industry Overviews

    Eli Lilly and Co.’s New Products Portfolio

    In 4Q16, Eli Lilly (LLY) reported Basaglar sales of $40 million from Japan and several European markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Innovative Health and Essential Health in 4Q16

    Pfizer’s (PFE) portfolio includes medicines, vaccines, and consumer healthcare products. It segregates its operations into Innovative Health and Essential Health.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences Initiated Phase 3 Trials to Evaluate Filgotinib

    Gilead Sciences (GILD) is exploring Filgotinib in multiple Phase 3 trials across various patient segments.

    By Margaret Patrick
  • uploads///XLV
    Company & Industry Overviews

    Is the 2017 Outlook for Healthcare Optimistic?

    The healthcare sector provided unimpressive returns in 2016. The Health Care Select Sector SPDR ETF fell 2.5% in 2016.

    By Sarah Sands
  • uploads///growth strategy
    Company & Industry Overviews

    Edwards Lifesciences Sees Growth on Long-Term Growth Strategy

    Edwards Lifesciences has established itself as a leader in the artificial heart valves market and has produced enormous long-term value over the years.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s News: Recent Acquisitions and Divestments

    Allergan completed the acquisition of Tobira Therapeutics, a San Francisco-based pharmaceuticals company, for $1.5 billion on September 20, 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The Pfizer-Medivation Deal, Completed in 3Q16

    On September 27, Pfizer completed the acquisition of Medivation. The stock transaction is valued at $81.50 per Medivation share for a total of ~$14 billion.

    By Mike Benson
  • uploads///XLV
    Company & Industry Overviews

    The Positive Performance of the Healthcare Sector

    The possible repeal of Obamacare might be an opportunity for healthcare stocks.

    By Sarah Sands
  • uploads///Chart
    Earnings Report

    Merck & Co.’s Profitability in 3Q16

    Merck revised its fiscal 2016 adjusted EPS range to be $3.71–$3.78, including a 1% negative impact of foreign exchange.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug

    Bristol-Myers Squibb’s revenues from Opdivo are estimated to be $938.8 million in 3Q16, as compared to $305 million in 3Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    JNJ’s Medical Devices Segment: How Did It Perform in 3Q16?

    Medical devices segment Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion between 3Q15 and 3Q16. This growth included an operational increase of 0.7% and a positive impact of foreign exchange. Cardiovascular care franchise The cardiovascular care franchise’s sales fell 13.9% to $451 million in 3Q16. This fall was due to the […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly and Co.’s 3Q16: The Major Developments

    As we discussed earlier, Eli Lilly and Co.’s (LLY) 3Q16 segment performance is expected to be positive for both its human pharmaceuticals and animal health segments.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Innovative Health and Essential Health Businesses

    Pfizer’s businesses Pfizer’s (PFE) portfolio comprises medicine, vaccines, and consumer healthcare products. The company has segregated its operations into two businesses: Innovative Health and Essential Health. Business segments  The above chart shows revenues for the last few quarters and revenue estimates for the next two quarters. Pfizer’s Innovative Health segment, which was previously referred to as […]

    By Mike Benson
  • uploads///danaher acquires cepheid
    Healthcare

    How Cepheid Fits Strategically into DHR’s Portfolio

    The acquisition of Cepheid (CPHD) in the strategic sense is a gateway for Danaher (DHR) to breathe life into its limited molecular testing capabilities.

    By Shannon Black
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.